

North East Onco Care Limited

July 02, 2024

Facilities/Instruments	Amount (₹ crore)	Rating ¹	Rating Action	
Long Term Bank Facilities	15.00	CARE B; Stable; ISSUER NOT COOPERATING*	Rating continues to remain under ISSUER NOT COOPERATING category	

Details of instruments/facilities in Annexure-1

Rationale and key rating drivers

CARE Ratings Ltd. had, vide its press release dated April 12, 2023, placed the rating(s) of North East Onco Care Limited (NEOCL) under the 'issuer non-cooperating' category as NEOCL had failed to provide information for monitoring of the rating and had not paid the surveillance fees for the rating exercise as agreed to in its Rating Agreement. NEOCL continues to be non-cooperative despite repeated requests for submission of information through e-mails, phone calls and a letter/email dated June 21, 2024, June 24, 2024 and June 25, 2024.

In line with the extant SEBI guidelines, CARE Ratings Ltd. has reviewed the rating on the basis of the best available information which however, in CARE Ratings Ltd.'s opinion is not sufficient to arrive at a fair rating.

Users of this rating (including investors, lenders and the public at large) are hence requested to exercise caution while using the above rating(s).

Analytical approach: Standalone

Outlook: Stable

Detailed description of the key rating drivers:

Please refer to PR dated April 12, 2023

Applicable criteria

CARE Ratings' criteria on information adequacy risk and issuer non-cooperation

Policy on default recognition

Criteria on Assigning 'Outlook' or 'Rating Watch' to Credit Ratings

About the company

North East Onco Care Ltd. (NEOCL) was incorporated on October 28, 2003. It is an Assam-based company engaged in healthcare business for cancer treatment with around 75 bed capacity as on October 31, 2020. It is the first comprehensive Cancer care center of its kind in North East India under private sector. The Company has been operating as a state of art cancer hospital and research center for almost 10 years now as a brand name "North East Cancer Hospital and Research Institute". The institute is recognized by UICC (Union for International Cancer Control), Geneva. The company is managed by a six-board member headed by Mr. Ganesh Tamuli, Chairman (60 years), Dr. Munindra Narayan Baruah (aged - 59 years), MD and Dr. Pranab Malla Baruah (68 years), Whole time Director, Dr. Munindra Narayan Baruah is a qualified (MS, FICS) and renowned doctor in the field of Head & Neck Oncology.

Brief Financials (Rs. crore)	March 31, 2022 (A)	March 31, 2023 (A)
Total operating income	19.98	18.18
PBILDT	2.97	1.22
PAT	1.80	0.78
Overall gearing (times)	1.61	1.21
Interest coverage (times)	13.12	4.92

A: Audited, Note: 'the above results are latest financial results available'

Status of non-cooperation with previous CRA: Not applicable

Any other information: Not applicable

Rating history for last three years: Please refer Annexure-2

¹Complete definition of the ratings assigned are available at www.careedge.in and other CARE Ratings Ltd.'s publications

1 CARE Ratings Ltd.

^{*}Issuer did not cooperate; based on best available information.



Covenants of rated instrument / facility: Detailed explanation of covenants of the rated instruments/facilities is given in Annexure-3

Complexity level of various instruments rated: Annexure-4

Lender details: Annexure-5

Annexure-1: Details of instruments/facilities

Name of the Instrument	ISIN	Date of Issuance (DD-MM-YYYY)	Coupon Rate (%)	Maturity Date (DD- MM-YYYY)	Size of the Issue (₹ crore)	Rating Assigned along with Rating Outlook
Fund-based - LT- Term Loan	-		-	March 2028	15.00	CARE B; Stable; ISSUER NOT COOPERATING*

^{*}Issuer did not cooperate; based on best available information.

Annexure-2: Rating history for the last three years

	Name of the Instrument/ Bank Facilities	Current Ratings			Rating History			
Sr. No.		Туре	Amount Outstandi ng (₹ crore)	Rating	Date(s) and Rating(s) assigned in 2024- 2025	Date(s) and Rating(s) assigned in 2023- 2024	Date(s) and Rating(s) assigned in 2022- 2023	Date(s) and Rating(s) assigned in 2021- 2022
1	Fund-based - LT- Term Loan	LT	15.00	CARE B; Stable; ISSUER NOT COOPERATIN G*	-	1)CARE B; Stable; ISSUER NOT COOPERAT ING* (12-Apr- 23)	-	1)CARE B+; Stable; ISSUER NOT COOPERAT ING* (28-Feb- 22) 2)CARE BB-; Stable (08-Apr- 21)

^{*}Issuer did not cooperate; based on best available information.

LT: Long term

Annexure-3: Detailed explanation of covenants of the rated instruments/facilities: Not applicable

Annexure-4: Complexity level of the various instruments rated

Sr. No.	Name of the Instrument	Complexity Level
1	Fund-based - LT-Term Loan	Simple

Annexure-5: Lender details

To view the lender wise details of bank facilities please <u>click here</u>

Note on the complexity levels of the rated instruments: CARE Ratings has classified instruments rated by it on the basis of complexity. Investors/market intermediaries/regulators or others are welcome to write to care@careedge.in for any clarifications.

2 CARE Ratings Ltd.



Contact us

Media Contact

Mradul Mishra Director

CARE Ratings Limited Phone: +91-22-6754 3596

E-mail: mradul.mishra@careedge.in

Relationship Contact

Ankur Sachdeva Senior Director

CARE Ratings Limited Phone: +91-22-6754 3444

E-mail: Ankur.sachdeva@careedge.in

Analytical Contacts

Shachee Nakul Vyas Assistant Director CARE Ratings Limited

Phone: 079-40265665

E-mail: shachee.tripathi@careedge.in

Aniket Shringarpure Lead Analyst

CARE Ratings Limited Phone: 079-40265659

E-mail: aniket.shringarpure@careedge.in

Jekin Shah Analyst

CARE Ratings Limited E-mail: Jekin.Shah@careedge.in

About us:

Established in 1993, CARE Ratings is one of the leading credit rating agencies in India. Registered under the Securities and Exchange Board of India, it has been acknowledged as an External Credit Assessment Institution by the RBI. With an equitable position in the Indian capital market, CARE Ratings provides a wide array of credit rating services that help corporates raise capital and enable investors to make informed decisions. With an established track record of rating companies over almost three decades, CARE Ratings follows a robust and transparent rating process that leverages its domain and analytical expertise, backed by the methodologies congruent with the international best practices. CARE Ratings has played a pivotal role in developing bank debt and capital market instruments, including commercial papers, corporate bonds and debentures, and structured credit.

Disclaimer:

The ratings issued by CARE Ratings are opinions on the likelihood of timely payment of the obligations under the rated instrument and are not recommendations to sanction, renew, disburse, or recall the concerned bank facilities or to buy, sell, or hold any security. These ratings do not convey suitability or price for the investor. The agency does not constitute an audit on the rated entity. CARE Ratings has based its ratings/outlook based on information obtained from reliable and credible sources. CARE Ratings does not, however, guarantee the accuracy, adequacy, or completeness of any information and is not responsible for any errors or omissions and the results obtained from the use of such information. Most entities whose bank facilities/instruments are rated by CARE Ratings have paid a credit rating fee, based on the amount and type of bank facilities/instruments. CARE Ratings or its subsidiaries/associates may also be involved with other commercial transactions with the entity. In case of partnership/proprietary concerns, the rating/outlook assigned by CARE Ratings is, inter-alia, based on the capital deployed by the partners/proprietors and the current financial strength of the firm. The ratings/outlook may change in case of withdrawal of capital, or the unsecured loans brought in by the partners/proprietors in addition to the financial performance and other relevant factors. CARE Ratings is not responsible for any errors and states that it has no financial liability whatsoever to the users of the ratings of CARE Ratings. The ratings of CARE Ratings do not factor in any rating-related trigger clauses as per the terms of the facilities/instruments, which may involve acceleration of payments in case of rating downgrades. However, if any such clauses are introduced and triggered, the ratings may see volatility and sharp downgrades.

For the detailed Rationale Report and subscription information, please visit www.careedge.in

3 CARE Ratings Ltd.